Smart implants for delivering therapeutic proteins to treat hemophilia A
Official title: SMART BIOELECTRONIC IMPLANTS FOR CONTROLLED DELIVERY OF THERAPEUTIC PROTEINS IN VIVO AND ITS APPLICATION IN LONG-TERM TREATMENT OF HEMOPHILIA A
Funded at Massachusetts Institute of Technology · NIH-11014418 · Data updated 2026-11-12
This study is exploring a new type of implant that can safely deliver helpful proteins to people with hemophilia A, aiming to provide a long-lasting and effective treatment while keeping the body’s immune system from attacking it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | May 1, 2022 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $544,206 |
| NIH project number | 5R01EB031992-04 |
| Project ID | NIH-11014418 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with hemophilia A who require ongoing treatment to manage their condition.
✕Less likely to help
Patients with other bleeding disorders or those who do not have hemophilia A may not benefit from this research.
What this research studies
This research focuses on developing advanced bioelectronic implants that can deliver therapeutic proteins in a controlled manner for the long-term treatment of hemophilia A. The approach involves encapsulating engineered cells that produce these proteins within a device that protects them from the immune system while allowing necessary nutrients and oxygen to reach the cells. By integrating electronic components into the implant, the researchers aim to enhance its functionality and longevity, addressing challenges such as inflammation and inadequate nutrient supply. This innovative method could provide a more effective and sustainable treatment option for patients with hemophilia A.
Why it matters
Potential benefit: If successful, this research could lead to a breakthrough treatment for hemophilia A, reducing the need for frequent injections and improving patients' quality of life.
How similar studies have gone: While the concept of cell encapsulation has been explored, this specific approach integrating bioelectronics is novel and has not been extensively tested in humans.
Where this research is happening
-
Massachusetts Institute of Technology
Cambridge, United States Active
Researchers
- Principal investigator: Anderson, Daniel G — Massachusetts Institute of Technology
- Study coordinator: Anderson, Daniel G
Related research
Other NIH-funded projects on the same topics.
-
cGMP production of FVIII-making placental cells to help people with Hemophilia A
A new, patient-friendly therapy aims to make FVIII-producing placental cells in the lab to help adults with Hemophilia A, potentially offering a longer-lasting and more affordable treatment.
-
A safer, longer-lasting gene delivery approach for Hemophilia A using improved nonviral vectors
Researchers are testing a new type of nonviral gene delivery that could provide longer expression of a therapeutic gene for adults with Hemophilia A.
-
Hemophilia A: studying why some people develop inhibitors to FVIII across families
This NIH grant funds a multi-year program to follow families affected by severe hemophilia A to understand why some individuals develop antibodies against factor VIII.
-
Intraosseous delivery of gene therapy vectors for hemophilia A
A gene therapy approach using vectors delivered into bone to help people with hemophilia A reduce or eliminate the need for frequent FVIII treatments.
-
Targeting FVIII production to eye-opening blood vessels in hemophilia A
Aims to improve treatment for people with hemophilia A by directing how the body makes clotting factor VIII, using a targeted gene-delivery approach.
-
Platelet-targeted FVIII Gene Therapy for Hemophilia A
A gene therapy approach aims to make platelets carry FVIII to help people with hemophilia A, even if they have inhibitors against FVIII.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.